PMS2 and sebaceous gland neoplasm: Based on our findings, a potential testing strategy for people with MLH1/PMS2-deficient sebaceous neoplasms would be initial germline MMR gene testing to identify a MLH1 pathogenic variant coupled with MLH1 epimutation testing (Supplementary Fig. 1).